Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qishen Yiqi Diwan
- Development stage
- Unknown
- Lead developer
- Tasly Pharmaceutical
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Qishen Yiqi Diwan (also known as Qishen Yiqi Dripping Pills or QSYQ) is a patented traditional Chinese medicine (TCM) formula developed and manufactured by Tasly Pharmaceutical Group. It is composed of extracts from four main herbs: *Astragalus membranaceus* (Huangqi), *Salvia miltiorrhiza* (Danshen), *Panax notoginseng* (Sanqi), and *Dalbergia odorifera* (Jiangxiang). Approved by the China National Medical Products Administration (NMPA) in 2003, it is primarily indicated for the treatment of cardiovascular diseases, including coronary heart disease, myocardial infarction, and ischemic heart failure. It is also being evaluated for the prevention of acute exacerbations in chronic obstructive pulmonary disease (COPD). Qishen Yiqi Diwan works through multi-target mechanisms, including anti-inflammatory, anti-fibrotic, antioxidant, and cardioprotective pathways, improving cardiac function and microcirculation.
- Brand names
- Qishen Yiqi DiwanQishen Yiqi Dripping Pills
- Other names
- Qi Shen Yi Qi Di WanQiseng Yiqi DiwanQishen Yiqi Drop PillQishen Yiqi Drop PillsQishen Yiqi Dropping PillQishen Yiqi PillsQSYQ
02
Targets
ACE (Angiotensin Converting Enzyme)POSTN (Periostin protein)AGTR1 (Angiotensin II Type-1 receptor)NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)
Beyond the preview
Go deeper on Qishen Yiqi Diwan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Qishen Yiqi Diwan.